These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30671881)

  • 1. Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
    Demerouti E; Karyofyllis P; Manginas A; Anthi A; Karatasakis G; Athanassopoulos G; Voudris V
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):99-105. PubMed ID: 30671881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled treprostinil and pulmonary arterial hypertension.
    Nadler ST; Edelman JD
    Vasc Health Risk Manag; 2010 Dec; 6():1115-24. PubMed ID: 21191432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.
    Langleben D; Barst RJ; Badesch D; Groves BM; Tapson VF; Murali S; Bourge RC; Ettinger N; Shalit E; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Stewart DJ; Long W
    Circulation; 1999 Jun; 99(25):3266-71. PubMed ID: 10385501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
    Osvaldo Cáneva J; Ossés JM
    Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
    Beghetti M
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral treprostinil in the treatment of pulmonary arterial hypertension.
    Feldman J; Habib N; Radosevich J; Dutt M
    Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents.
    Yamamoto K; Takeda Y; Takeda Y; Naniwa T; Narita H; Ohte N
    BMC Res Notes; 2014 Jun; 7():359. PubMed ID: 24920465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension.
    Gildea TR; Arroliga AC; Minai OA
    Cleve Clin J Med; 2003 Apr; 70 Suppl 1():S18-27. PubMed ID: 12716139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ten years' experience in continuous intravenous epoprostenol therapy in severe pulmonary arterial hypertension].
    Pombo Jiménez M; Escribano Subías P; Tello de Meneses R; Gómez-Sánchez MA; Delgado Jiménez J; Dalmau González-Gallarza R; Lázaro Salvador M; Hernández Rodríguez I; Tascón Pérez J; Sáenz de la Calzada C
    Rev Esp Cardiol; 2003 Mar; 56(3):230-5. PubMed ID: 12622952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.